{"nctId":"NCT01177384","briefTitle":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","startDateStruct":{"date":"2011-01-25","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":380,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin phosphate","Drug: Acarbose","Drug: Glimepiride"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo","Drug: Acarbose","Drug: Glimepiride"]}],"interventions":[{"name":"Sitagliptin phosphate","otherNames":["Januvia"]},{"name":"Comparator: Placebo","otherNames":[]},{"name":"Acarbose","otherNames":["Precose"]},{"name":"Glimepiride","otherNames":["AmarylÂ®","Glimy"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* has T2DM and is on acarbose alone at a stable dose of at least 50 mg t.i.d.(three times a day) for at least 10 weeks or on acarbose at a stable dose of at least 50 mg t.i.d. (three times a day) for at least 10 weeks in combination with another antihyperglycemic agent (AHA)\n* is at least 18 years of age (for participants in India: between 18 and 65 years of age)\n* male or female who is unlikely to conceive (not of reproductive potential, or agrees to remain abstinent or use \\[or have partner use\\] acceptable birth control if of reproductive potential)\n\nExclusion Criteria:\n\n* has a history of type 1 diabetes mellitus\n* use of thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, or insulin\n* has the following cardiovascular disorders: acute coronary syndrome; new or worsening symptoms of coronary heart disease; coronary artery intervention; stroke or transient ischemic neurological disorder\n* has liver or kidney disease\n* has cancer or any clinically significant disease or disorder as judged by the Investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24","description":"A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. Efficacy analyses treated data as missing after the initiation of rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":null},{"groupId":"OG001","value":"-0.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG. Efficacy analyses treated data as missing after the initiation of rescue therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.9","spread":null},{"groupId":"OG001","value":"-3.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced at Least One Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":191},"commonTop":[]}}}